Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SL277P is annotated as a pseudogene derived from the 7SL RNA sequence family, which is a component of the signal recognition particle (SRP) required for targeting secretory proteins to the endoplasmic reticulum in eukaryotic cells. However, RN7SL277P itself is a non-coding, likely non-functional copy that arose via reverse transcription and genomic integration[1][5][6][9]. Pseudogenes such as RN7SL277P are typically truncated or mutated, and there is no evidence that this locus encodes a functional RNA or protein product, nor is it involved in human disease, drug targeting, or biomarker development[1][5][6][9]. As a member of the widespread class of processed pseudogenes in the human genome, it does not serve as a valid therapeutic or diagnostic target. RN7SL277P should not be considered a canonical molecular target in biomedical research or drug development.
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 277, pseudogene (RN7SL277P).